MedTrace Logo

Oral OKT3 in Combination With Beta-D-Glucosylceramide

NCT00619372 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-02-04

No results posted yet for this study

Summary

This clinical study is designed to evaluate the safety of oral administration of the study drug anti CD3 (OKT3) in combination with β-D glucosylceramide \[GC\] .

Conditions

  • Healthy

Interventions

DRUG

OKT3

0.2 mg OKT3, PO (in the mouth) on day 1 through 5.

DRUG

OKT3, GC

0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5

DRUG

OKT3

1 mg OKT3, PO (in the mouth) on day 1 through 5

DRUG

OKT3, GC

1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5

DRUG

OKT3

5 mg OKT3, PO (in the mouth) on day 1 through 5

DRUG

GC

7.5 mg GC, PO (in the mouth) on day 1 through 5

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Ehud Zigmond, M.D. · Hadassah University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-04-30
Completion
2008-06-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619372 on ClinicalTrials.gov